Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4D-150 in Adults With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988Phase 3Active, not recruiting
- Sponsor
- 4D Molecular Therapeutics
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of 4D-150 in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by 4D Molecular Therapeutics. Primary endpoint: Best Corrected Visual Acuity ETDRS letter score at 52 weeks. Started Mar 2025; status: active, not recruiting.
02
Drugs
4D-150
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06864988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06864988.